Literature DB >> 22287683

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

P L Zinzani1, E Derenzini2, C Pellegrini2, L Rigacci3, A Fabbri4, L Gandolfi2, L Argnani2, B Casadei2, A Pulsoni5, M Gobbi6, A Perotti7, A Zaccaria8, M T Voso9, M G Cabras10, A De Renzo11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22287683     DOI： 10.1093/annonc/mdr633

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

2.  First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Authors:  Reyes Arranz; Ana García-Noblejas; Carlos Grande; Jimena Cannata-Ortiz; José J Sánchez; José-Antonio García-Marco; Concepción Aláez; Javier Pérez-Calvo; Pilar Martínez-Sánchez; Blanca Sánchez-González; Miguel-Angel Canales; Eulogio Conde; Alejandro Martín; Eva Arranz; María-José Terol; Antonio Salar; Dolores Caballero
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

Review 3.  Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

Authors:  Antonio C Sánchez Ruiz; Luis de la Cruz-Merino; Mariano Provencio Pulla
Journal:  Ther Adv Hematol       Date:  2014-06

4.  Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.

Authors:  Francesco Pisani; Rosa Sciuto; Maria Laura Dessanti; Diana Giannarelli; Ramy Kayal; Sandra Rea; Francesco Marchesi; Mirella Marino
Journal:  Exp Hematol Oncol       Date:  2015-06-24

5.  90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.

Authors:  Beatrice Casadei; Cinzia Pellegrini; Alessandro Pulsoni; Giorgia Annechini; Amalia De Renzo; Vittorio Stefoni; Alessandro Broccoli; Letizia Gandolfi; Federica Quirini; Lorenzo Tonialini; Alice Morigi; Lisa Argnani; Pier Luigi Zinzani
Journal:  Cancer Med       Date:  2016-03-14       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.